Metagenomi Therapeutics, Inc. (MGX)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Metagenomi Therapeutics, Inc. reported revenue of $25.21M, down 51.8% from the prior year. The company ran a net loss, with a net margin of -348.5%. It held $221.10M in total assets against $62.51M in total liabilities.
Key ratios (FY2025)
-380.9%
Operating margin
-348.5%
Net margin
-55.4%
Return on equity
-51.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $25.21M | $52.30M | $44.76M | — |
| Operating Income | -$96.01M | -$88.90M | -$78.49M | — |
| Net Income | -$87.87M | -$78.06M | -$68.25M | — |
| EPS (Diluted) | $-2.36 | $-2.36 | $-20.05 | — |
| Total Assets | $221.10M | $324.60M | $364.84M | — |
| Total Liabilities | $62.51M | $89.74M | $149.67M | — |
| Shareholders' Equity | $158.60M | $234.86M | -$135.58M | -$74.43M |
| Cash & Equivalents | $41.72M | $27.39M | $140.60M | — |
| Operating Cash Flow | -$88.89M | -$109.07M | -$91.41M | — |
| Capital Expenditures | $574.0K | $3.11M | $9.81M | — |
| Shares Outstanding | 37.62M | 37.42M | 3.40M | — |